• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

德国慕尼黑有代表性的 COVID-19 队列中的感染率和危险因素。

Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich.

机构信息

Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany.

German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany.

出版信息

Int J Environ Res Public Health. 2021 Mar 30;18(7):3572. doi: 10.3390/ijerph18073572.

DOI:10.3390/ijerph18073572
PMID:33808249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8038115/
Abstract

Given the large number of mild or asymptomatic SARS-CoV-2 cases, only population-based studies can provide reliable estimates of the magnitude of the pandemic. We therefore aimed to assess the sero-prevalence of SARS-CoV-2 in the Munich general population after the first wave of the pandemic. For this purpose, we drew a representative sample of 2994 private households and invited household members 14 years and older to complete questionnaires and to provide blood samples. SARS-CoV-2 seropositivity was defined as Roche N pan-Ig ≥ 0.4218. We adjusted the prevalence for the sampling design, sensitivity, and specificity. We investigated risk factors for SARS-CoV-2 seropositivity and geospatial transmission patterns by generalized linear mixed models and permutation tests. Seropositivity for SARS-CoV-2-specific antibodies was 1.82% (95% confidence interval (CI) 1.28-2.37%) as compared to 0.46% PCR-positive cases officially registered in Munich. Loss of the sense of smell or taste was associated with seropositivity (odds ratio (OR) 47.4; 95% CI 7.2-307.0) and infections clustered within households. By this first population-based study on SARS-CoV-2 prevalence in a large German municipality not affected by a superspreading event, we could show that at least one in four cases in private households was reported and known to the health authorities. These results will help authorities to estimate the true burden of disease in the population and to take evidence-based decisions on public health measures.

摘要

鉴于大量 SARS-CoV-2 轻症或无症状病例的存在,只有基于人群的研究才能提供有关大流行严重程度的可靠估计。因此,我们旨在评估疫情第一波过后慕尼黑普通人群中 SARS-CoV-2 的血清流行率。为此,我们从 2994 户私人家庭中抽取了一个有代表性的样本,并邀请 14 岁及以上的家庭成员填写问卷并提供血液样本。SARS-CoV-2 血清阳性定义为罗氏 N 泛 IgG≥0.4218。我们根据抽样设计、敏感性和特异性对流行率进行了调整。我们通过广义线性混合模型和置换检验调查了 SARS-CoV-2 血清阳性的危险因素和地理空间传播模式。与慕尼黑官方登记的 0.46%PCR 阳性病例相比,SARS-CoV-2 特异性抗体血清阳性率为 1.82%(95%置信区间 1.28-2.37%)。嗅觉或味觉丧失与血清阳性相关(优势比(OR)47.4;95%置信区间 7.2-307.0),感染在家庭内聚集。通过这项在未受超级传播事件影响的德国大型直辖市进行的 SARS-CoV-2 患病率的首次基于人群的研究,我们可以证明,在私人家庭中,至少每四个病例就有一个向卫生当局报告并被其知晓。这些结果将有助于当局估计人群中的真实疾病负担,并就公共卫生措施做出基于证据的决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/286ef10b02d5/ijerph-18-03572-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/fa364ea417d7/ijerph-18-03572-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/cd6a8b24a2b8/ijerph-18-03572-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/4bd3d285c1b2/ijerph-18-03572-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/f47968cead05/ijerph-18-03572-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/7c1a3477d1ff/ijerph-18-03572-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/286ef10b02d5/ijerph-18-03572-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/fa364ea417d7/ijerph-18-03572-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/cd6a8b24a2b8/ijerph-18-03572-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/4bd3d285c1b2/ijerph-18-03572-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/f47968cead05/ijerph-18-03572-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/7c1a3477d1ff/ijerph-18-03572-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52d/8038115/286ef10b02d5/ijerph-18-03572-g006.jpg

相似文献

1
Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich.德国慕尼黑有代表性的 COVID-19 队列中的感染率和危险因素。
Int J Environ Res Public Health. 2021 Mar 30;18(7):3572. doi: 10.3390/ijerph18073572.
2
The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant.代表 COVID-19 的慕尼黑队列(KoCo19):从大流行开始到德尔塔病毒变异。
BMC Infect Dis. 2023 Jul 13;23(1):466. doi: 10.1186/s12879-023-08435-1.
3
From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany).从第一波到第二波:德国慕尼黑前瞻性 COVID-19 队列(KoCo19)的随访。
BMC Infect Dis. 2021 Sep 8;21(1):925. doi: 10.1186/s12879-021-06589-4.
4
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.家庭二次感染 COVID-19 的发生率及其在中国广州的相关决定因素:一项回顾性队列研究。
Lancet Infect Dis. 2020 Oct;20(10):1141-1150. doi: 10.1016/S1473-3099(20)30471-0. Epub 2020 Jun 17.
5
Inappropriate risk perception for SARS-CoV-2 infection among Italian HCWs in the eve of COVID-19 pandemic.在新冠疫情前夕,意大利医护人员对新冠病毒感染存在不当的风险认知。
Acta Biomed. 2020 May 14;91(3):e2020040. doi: 10.23750/abm.v91i3.9727.
6
Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study.2020年7月至8月在马萨诸塞州进行的血清学调查以估计成人中SARS-CoV-2感染的累积发病率(血清大规模研究):一项基于邮件的横断面研究。
medRxiv. 2021 May 6:2021.03.05.21249174. doi: 10.1101/2021.03.05.21249174.
7
EPICOVID19 protocol: repeated serological surveys on SARS-CoV-2 antibodies in Brazil.EPICOVID19方案:巴西针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗体的重复血清学调查
Cien Saude Colet. 2020 Sep;25(9):3573-3578. doi: 10.1590/1413-81232020259.25532020. Epub 2020 Aug 28.
8
Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.估计的社区 SARS-CoV-2 抗体血清流行率-佐治亚州两个县,2020 年 4 月 28 日-5 月 3 日。
MMWR Morb Mortal Wkly Rep. 2020 Jul 24;69(29):965-970. doi: 10.15585/mmwr.mm6929e2.
9
Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: a community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-CoV-2 antibodies in London, UK.嗅觉和味觉障碍与女性性别相关,并与 SARS-CoV-2 抗体阳性者的持续性嗅觉和/或味觉丧失有关:一项基于社区的队列研究,在英国伦敦调查了 SARS-CoV-2 抗体阳性和阴性者急性嗅觉和/或味觉丧失的临床过程和恢复情况。
BMC Infect Dis. 2021 Feb 25;21(1):221. doi: 10.1186/s12879-021-05927-w.
10
[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].[意大利北部皮埃蒙特大区博尔戈塞西亚人群中抗SARS-CoV-2 IgG/IgM抗体的血清流行率:封锁后时期的监测策略?]
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):200-206. doi: 10.19191/EP20.5-6.S2.119.

引用本文的文献

1
Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection.野生型感染250天后康复的未接种疫苗个体中可检测到的SARS-CoV-2特异性免疫反应。
PLoS One. 2025 Jun 11;20(6):e0325923. doi: 10.1371/journal.pone.0325923. eCollection 2025.
2
Sero-prevalence of SARS-CoV-2 antibodies in Ethiopia: Results of the National Population Based Survey, 2021.埃塞俄比亚2019冠状病毒病抗体血清流行率:2021年全国人口调查结果
PLoS One. 2025 May 6;20(5):e0313791. doi: 10.1371/journal.pone.0313791. eCollection 2025.
3
Differential DNA methylation 7 months after SARS-CoV-2 infection.

本文引用的文献

1
Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany.德国超级传播事件中 SARS-CoV2 的感染病死率。
Nat Commun. 2020 Nov 17;11(1):5829. doi: 10.1038/s41467-020-19509-y.
2
A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children.一项公共卫生抗体筛查表明,儿童感染 SARS-CoV-2 的比例比报告病例高 6 倍。
Med. 2021 Feb 12;2(2):149-163.e4. doi: 10.1016/j.medj.2020.10.003. Epub 2020 Oct 29.
3
Epidemiology and transmission dynamics of COVID-19 in two Indian states.
新型冠状病毒感染7个月后的DNA甲基化差异
Clin Epigenetics. 2025 Apr 18;17(1):60. doi: 10.1186/s13148-025-01866-4.
4
Underreporting of Cases in the COVID-19 Outbreak of Borriana (Spain) during Mass Gathering Events in March 2020: A Cross-Sectional Study.2020年3月西班牙博里亚纳大规模聚集活动期间新冠疫情病例报告不足情况:一项横断面研究
Epidemiologia (Basel). 2024 Aug 9;5(3):499-510. doi: 10.3390/epidemiologia5030034.
5
Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection.接种疫苗和奥密克戎突破性感染后,新冠病毒特异性B细胞和T细胞保护性免疫反应的演变
iScience. 2024 May 28;27(6):110138. doi: 10.1016/j.isci.2024.110138. eCollection 2024 Jun 21.
6
Estimated relative potential for airborne SARS-CoV-2 transmission in a day care centre.日托中心空气中严重急性呼吸综合征冠状病毒2传播的估计相对可能性。
Heliyon. 2024 May 6;10(9):e30724. doi: 10.1016/j.heliyon.2024.e30724. eCollection 2024 May 15.
7
A Dried Blood Spot protocol for high-throughput quantitative analysis of SARS-CoV-2 RBD serology based on the Roche Elecsys system.基于罗氏 Elecsys 系统的高通量定量分析 SARS-CoV-2 RBD 血清学的干血斑检测方案。
Microbiol Spectr. 2024 Apr 2;12(4):e0288523. doi: 10.1128/spectrum.02885-23. Epub 2024 Mar 1.
8
Persistent immune abnormalities discriminate post-COVID syndrome from convalescence.持续性免疫异常可将新冠后综合征与恢复期区分开来。
Infection. 2024 Jun;52(3):1087-1097. doi: 10.1007/s15010-023-02164-y. Epub 2024 Feb 7.
9
The Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf): Risk Factors and Determinants of Immune Response in Healthcare Workers.慕尼黑前瞻性 COVID-19 免疫后血清队列研究(KoCo-Impf):医护人员免疫反应的风险因素和决定因素。
Viruses. 2023 Jul 18;15(7):1574. doi: 10.3390/v15071574.
10
The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant.代表 COVID-19 的慕尼黑队列(KoCo19):从大流行开始到德尔塔病毒变异。
BMC Infect Dis. 2023 Jul 13;23(1):466. doi: 10.1186/s12879-023-08435-1.
印度两个邦的 COVID-19 流行病学和传播动力学。
Science. 2020 Nov 6;370(6517):691-697. doi: 10.1126/science.abd7672. Epub 2020 Sep 30.
4
The engines of SARS-CoV-2 spread.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)传播的驱动因素。
Science. 2020 Oct 23;370(6515):406-407. doi: 10.1126/science.abd8755.
5
A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates.对已发表的关于 COVID-19 感染病死率的研究数据的系统回顾和荟萃分析。
Int J Infect Dis. 2020 Dec;101:138-148. doi: 10.1016/j.ijid.2020.09.1464. Epub 2020 Sep 29.
6
Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases.气道中 ACE2 的表达:对慢性炎症性呼吸道疾病患者 COVID-19 风险和疾病管理的影响。
Clin Exp Allergy. 2020 Dec;50(12):1313-1324. doi: 10.1111/cea.13746. Epub 2020 Oct 6.
7
Systematic Review and Meta-analysis of Smell and Taste Disorders in COVID-19.新型冠状病毒肺炎嗅觉和味觉障碍的系统评价与荟萃分析
OTO Open. 2020 Sep 11;4(3):2473974X20957975. doi: 10.1177/2473974X20957975. eCollection 2020 Jul-Sep.
8
Humoral Immune Response to SARS-CoV-2 in Iceland.冰岛人针对 SARS-CoV-2 的体液免疫反应。
N Engl J Med. 2020 Oct 29;383(18):1724-1734. doi: 10.1056/NEJMoa2026116. Epub 2020 Sep 1.
9
Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing.首个针对抗 SARS-CoV-2 抗体检测的外部质量评估(EQA)计划的结果。
Clin Chem Lab Med. 2020 Aug 27;58(12):2121-2130. doi: 10.1515/cclm-2020-1183.
10
Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error.调整冠状病毒流行率估计值以消除实验室检测试剂盒误差。
Am J Epidemiol. 2021 Jan 4;190(1):109-115. doi: 10.1093/aje/kwaa174.